HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Cartesian Therapeutics (NASDAQ:RNAC) and maintained a price target of $45.
September 13, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Cartesian Therapeutics, maintaining a $45 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $45 price target by a reputable analyst suggests positive sentiment and confidence in Cartesian Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100